The Vaccination Advisory Group warns that the American variants show greater transmission capacity
Mexico City- Gustavo Reyes Terán, coordinator of the National Institutes of Health and Advanced Specialty Hospital, warned that in some states in the United States, the 1.1.7 variant of SARS-CoV-2 Shows greater dissemination capabilities, and may have greater replication capabilities.
He said: “Two recent studies, one was carried out yesterday and the other two or three days ago, show that it may lead to a higher mortality rate, although this is not yet universally accepted. The problem is that you have to maintain alert.”
Reyes Terán, who made the recent recommendations of the Covid-19 Vaccine Technical Advisory Group (GTAV), said that people believe that regardless of the recent Covid-19 infection caused by the Covid-19 vaccine in Mexico, the vaccination plan is Should continue. Known as a variant of Britain and Brazil.
He said at the “National Vaccination Policy: Recommendations of the Technical Advisory Group for the Covid-19 Vaccine” forum organized by the National Institute of Public Health: “They are two of the three variants of current global concern.”
They temporarily discard the vaccine mixture
Reyes Terán said the technical advisory group also determined that the second dose should be the same vaccine that people used in the first use.
“GTAV recommends using the same vaccine for the second dose, and pay attention to the results of clinical trials that have already begun on the possibility of replacing the vaccine. These results are expected to appear in the next few weeks or within a few months. ,”He said.
Experts mentioned that Pfizer’s second dose can be used three to six weeks after the first dose, while AstraZeneca can be used eight to twelve weeks.
Experts said: “Adjusting the dose interval should not affect the possibility of receiving a second dose of the vaccine; so far, there is insufficient evidence to recommend a single dose of these two vaccines (neither Sputnik nor Sinovac).”
He clarified that these recommendations can be revised when more data is available.
The coordinator pointed out that, so far, the WHO Vaccination Strategy Advisory Group has not issued prescription recommendations for artificial satellites and Sinovac. Therefore, GTAV recommends following the indications of Cefprisi.
Regarding the use of Sinovac vaccine in the elderly, he recognized that it is still limited, but GTAV recommends its use in populations in this field.
He explained: “This recommendation is based on the information available so far and the recommendations of the World Health Organization.”
“It has been recognized that there is limited evidence of effectiveness in the elderly, especially in the Sinovac vaccine, but the risk of serious illness in this population from the Covid-19 population is very high, and there is evidence in the phase 3 study that, in particular, A good immune response induced by the vaccine, and the vaccine is safe.”
Regarding the use of vaccines in people receiving blood transfusion and its derivatives, GTAV recognizes that there may be problems with its use due to the presence of antibodies that may interfere with the immune response induced by the vaccine, so it is recommended from the 90th day after blood transfusion.
He pointed out that GTAV and the National Blood Transfusion Center did not find a reason for delaying the infusion of red blood cell vaccine, because it is assumed that it does not carry plasma components, and the plasma components in the plasma may interfere with the response caused by the vaccine.